Cardiff Oncology (CRDF) Reports 72% ORR in Phase 2 Onvansertib Colorectal Cancer Trial

Cardiff Oncology (NASDAQ: CRDF) presented positive Phase 2 data for its lead candidate onvansertib in metastatic colorectal cancer on June 2, 2026, highlighting a 72% objective response rate (ORR) when combined with standard-of-care chemotherapy. The trial evaluated the oral PLK1 inhibitor in a second-line setting for patients with KRAS-mutated tumors. The 72% ORR significantly exceeded historical response rates for conventional therapies, which typically fall in the single-digit to low-teen percentages. The company said the results support an accelerated approval pathway and plans to request an end-of-Phase 2 meeting with the FDA. Shares of Cardiff have risen sharply in premarket trading following the announcement.